The New England journal of medicine
-
Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder. ⋯ Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia. (Funded by the German Research Foundation.).
-
Letter Case Reports
Rapid Sequencing-Based Diagnosis of Thiamine Metabolism Dysfunction Syndrome.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. ⋯ In this trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 274 ClinicalTrials.gov number, NCT02632409.).